Search results for Belimumab

Belimumab, Abbexa, abx831148

Belimumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting TNFSF13B/CD257, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Belimumab is an intravenous immunosupressant for the adjunctive treatment of systemic lupus erythematosus (SLE). More specifically, it is a fully human recombinant IgG1λ monoclonal antibody produced from a recombinant NS0 cell line stably transfected with the belimumab heavy chain and light chain genes. It is the first biological treatment approved for the indication of SLE. Concomitant use with live or inactivated vaccines must be avoided. Belimumab was FDA approved on March 9, 2011. Belimumab consists of 2 heavy chains, and 2 light chains of the lambda subclass. Each heavy chain contains 452 amino acid residues and each light chain contains 214 amino acid residues. There are 3 post-translational modifications: a conserved N-linked glycosylation on the CH2 domain at Asn 303 of the heavy chain, the conversion of the N-terminal glutamine residue of the heavy chain into pyroglutamate, and loss of C-terminal lysine residue of the heavy chain.

Belimumab ELISA Kit, Abbexa, abx392577

Belimumab ELISA Kit is a quantitative ELISA kit for detection of Belimumab.

Anti-Belimumab Polyclonal Antibody, AntibodySystem, PAJ85301

Belimumab Biosimilar - Research Grade, ichor.bio, ICH5080

Detects human TNFSF13B. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Belimumab.

Research Grade Belimumab (HV212016), abinScience, HV212016